Capital Access & Adoption
OBIO® supports early-stage and venture-backed life sciences and health tech companies by enabling them to:
Raise capital
Train their start-up teams
Develop early commercialization strategies
Drive market adoption through connections with healthcare systems, and strategic MedTech & Pharma partners
Access critical infrastructure resources
Through the Health Commercialization Access Program, we support the commercialization journey of early-stage companies with technology and commercial development by providing real-time advice on securing angel capital through HealthMINT®. As companies transition from Seed to Series A, we offer two competitive programs: CAAP®, which prepares executive teams for financing, and EAHN™, which supports commercial adoption and procurement.
Some companies OBIO® has supported over the years:
HealthMINT® increases the preparedness of life science companies to apply for competitive grants, engage with early investors and pressure test your go-to-market and R&D strategy with experts.
The Capital Access Advisory Program (CAAP®) provides post-seed financing support by preparing executive teams to engage with the VC community, corporate development, and by identifying key industry expertise.
The Early Adopter Health Network (EAHN™) promotes Canadian companies with technologies ready for commercial adoption to a network of healthcare organizations, that evaluates and disseminates these innovations domestically for procurement, paving the way for international export.
